Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

PURPOSE: Phase I results of this phase I/II study showed that pamiparib 60 mg twice a day had antitumor activity and an acceptable safety profile in Chinese patients with advanced cancer, including epithelial ovarian cancer. PATIENTS AND METHODS: This open-label phase II study was conducted in China...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaohua, Zhu, Jianqing, Wang, Jing, Lin, Zhongqiu, Yin, Rutie, Sun, Wei, Zhou, Qi, Zhang, Songling, Wang, Danbo, Shi, Hong, Gao, Yunong, Huang, Yi, Li, Guiling, Wang, Xiuli, Cheng, Ying, Lou, Ge, Gao, Qinglei, Wang, Li, Du, Xiuping, Pan, Mei, Mu, Xiyan, Li, Li, Li, Miao, Mu, Song, Kong, Beihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377729/
https://www.ncbi.nlm.nih.gov/pubmed/34844979
http://dx.doi.org/10.1158/1078-0432.CCR-21-1186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377729/
https://www.ncbi.nlm.nih.gov/pubmed/34844979
http://dx.doi.org/10.1158/1078-0432.CCR-21-1186

Ejemplares similares